netFormulary North Central London NHS
Joint Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Section

08.01 Cytotoxic drugs
Side-effects of cytotoxic drugs
Drugs for cytotoxic-induced side-effects
08.01.01 Alkylating drugs
08.01.02 Anthracyclines and other cytotoxic antibiotics
08.01.03 Antimetabolites
08.01.04 Vinca alkaloids and etoposide
08.01.05 Other antineoplastic drugs
Amsacrine
Arsenic trioxide
Bevacizumab
Bexarotene
Bortezomib
Brentuximab vedotin
Cetuximab
Crisantaspase
Dacarbazine and Temozolomide
Erlotinib
Hydroxycarbamide
Imatinab
Ipilimumab
Mitotane
Panitumumab
Pentostatin
Platinum compounds
Porfimer sodium and temoporfin
Procarbazine
Protein kinase inhibitors
Taxanes
Topoisomerase I inhibitors
Trabectedin
Trastuzumab
Tretinoin
Vismodegib
08.02 Drugs affecting the immune response
Immunosuppressant therapy
08.02.01 Antiproliferative immunosuppressants
08.02.02 Corticosteroids and other immunosuppressants
08.02.03 Anti-lymphocyte monoclonal antibodies
08.02.04 Other immunomodulating drugs
Interferon Alfa
Interferon beta
Interferon gamma
Aldesleukin
BCG bladder instillation
Canakinumab
Dimethyl fumarate
Fingolimod
Glatiramer acetate
Histamine
Lenalidomide, pomalidomide, and thalidomide
Mifamurtide
Natalizumab
Teriflunomide
08.03 Sex hormones and hormone antagonists in malignant disease
08.03.01 Oestrogens
08.03.02 Progestogens
08.03.03 Androgens
08.03.04 Hormone antagonists
08.03.04.01 Breast cancer
08.03.04.02 Prostate cancer and gonadorelin analogues
Gonadorelin analogues
Anti-androgens
08.03.04.03 Somatostatin analogues
netFormulary